Redwood City, CA, February 24, 2025 – FlemingMartin is pleased to announce that Revolution Medicines (Nasdaq: RVMD), a late clinical stage oncology company developing novel targeted therapies for RAS-addicted cancers, has hired Brad Turcott as Vice President of Talent Acquisition.
Brad possesses 30 years of TA and HR experience spanning roles in large, mid-size, and startup corporate environments. Most recently, Brad served as the Head of Talent Acquisition at Seagen (acquired by Pfizer for $43B in 2023). During his 16-year tenure at SGEN, Brad built out the TA function and played an instrumental role in scaling the company from 180 to nearly 4,000 employees, while supporting the successful discovery, development, and commercialization of multiple cancer medicines.
Earlier in his career, Brad held Human Resources roles of increasing scope and responsibility with InfoSpace, Eli Lilly (NYSE: LLY), AT&T (NYSE: T), Hewlett-Packard (NYSE: HPQ), and Honeywell (Nasdaq: HON). Brad earned his master’s degree in human resources and industrial relations from the University of Minnesota, and he received his undergraduate degree from Michigan State University.
